“I believe this is the first time this has happened in the history of cancer,” said Dr. Luis A. Diaz Jr., one of the authors of the study paper, according to The Daily Wire.
“We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti-PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair-deficient stage II or III rectal adenocarcinoma,” the study said. “The treatment was to be followed by standard chemotherapy and surgery.”
WATCH: NFL LEGEND LAWRENCE TAYLOR ENDORSES TRUMP FOR PRESIDENT
Remarkably, the patients who took the medication which “unmasks cancer cells allowing the immune system to destroy them,” did not need additional cancer treatment.
Dr. Kimmie Ng, a colorectal expert from the Dana-Farber Cancer Institute, called the trial results “remarkable” and “unprecedented.” WATCH: THE BEST KAMALA IMPRESSION AT A TRUMP RALLY
All the patients “had a clinical complete response, with no evidence of tumor on magnetic resonance imaging,” explained the study paper. “At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range 6 to 25 months).”
DEBATE DRAMA: WILL TRUMP BAIL? 'VIEW' HOST SAYS ‘COUNT ON IT,’ DESPITE CONFIRMED DATES
According to Science Daily, Dr. Hanna K. Sanoff, of UNC Lineberger Comprehensive Cancer Center, describes that 45,000 people in the U.S. were analyzed with rectal cancer last year, and many of those cases were in people younger than 65. She adds that historical treatment of the disease, such as radiation, chemotherapy and surgery, can be debilitating. Sanoff, a professor in the UNC School of Medicine Division of Oncology, says that the new study gives hope to these people.
DECEIVED AND DEPLOYED: HOW HUNDREDS OF SRI LANKANS WERE TRICKED INTO FIGHTING RUSSIA'S WAR
“These initial findings of the remarkable benefit with the use of dostarlimab are very encouraging but also need to be viewed with caution until the results can be replicated in a larger and more diverse population,” Sanoff said, adding that “although quality of life measures have not been reported yet, it’s encouraging that some of the most difficult symptoms, such as pain and bleeding, all resolved with the use of dostarlimab.”
WHISTLEBLOWER ALERT: INSIDER CONFESSES EPA'S FATEFUL ERRORS AMID TOXIC CHAOS IN EAST PALESTINE
On a different matter, though related, two "smart bomb" drugs are offering new hope to women with aggressive breast cancers, a pair of clinical trials show.
Both medications are antibody-drug conjugates, including a chemo drug that's been wedded to an antibody that delivers the chemotherapy directly to cancer cells.
SEE ANTONY BLINKEN'S ‘ROCKIN’ RESPONSE TO UKRAINIAN CONFLICT
"That's a way to take the chemo right to the cancer cells and spare the rest of the body a lot of toxicity," said Dr. Shanu Modi, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York City. "The antibody takes the chemo right to the cancer cells. When the antibody finds its target, the whole complex gets internalized into the cell, and then the chemo gets released inside the cancer cell."
BILLIONAIRE'S PLAYBOOK: HOW SOROS-BACKED GROUPS PLAN TO MUZZLE YOUR VOICE
Modi served as head researcher for the first drug, Enhertu (trastuzumab deruxtecan), which stalled cancer progression for nearly double the time of standard chemotherapy – 10.1 versus 5.4 months – in a select group of patients with advanced breast cancer.
WATCH: RAGING ANTI-SEMITIC IMAM ON VIDEO FOR THE WORLD TO SEE...
The other drug, Trodelvy (sacituzumab govitecan), also resulted in longer progression-free survival compared to standard chemotherapy in certain cancer patients, according to results presented Saturday at the American Society of Clinical Oncology (ASCO) annual meeting, in Chicago. Such research is regarded as preliminary until published in a peer-reviewed journal.
Discover alternative ideas that will make you think
Engage in mind bending debate
Earn points, rise in rank, have fun
